The sarcopenia treatment market value is expected to reach US$ 5,264.76 million by 2030 from US$ 3,397.62 million in 2022.

The report highlights trends prevailing in the market and factors driving and hindering the growth of the sarcopenia treatment market.

The growing awareness of sarcopenia and its negative impact on health presents a significant scope for advancements in the fields of healthcare and geriatric care. Many advocacy groups and organizations are proactively taking steps to raise the awareness of sarcopenia among the masses. These organizations often work with medical professionals to keep the public updated on the various aspects of pathogenicity, target patients, prevention, and treatments, among other aspects, along with underlining the value of prompt diagnosis and treatment. The Office on Women's Health (OWH) of the US Department of Health and Human Services launched the national campaign "Stronger than Sarcopenia" in 2023 to magnify the awareness of sarcopenia in women. Research by Health and Human Services shows that more than 45% of the elderly population in the US suffers from sarcopenia, and millions of younger individuals are at risk of developing this condition later in their lives. In line with OWH's "Stronger than Sarcopenia" campaign, women are urged to discuss sarcopenia with their healthcare providers, followed by undergoing screen for the illness and taking appropriate therapy if required.

Sarcopenia has been included in the curricula of medical schools and training programs for healthcare professionals such as physicians, nurses, and physical therapists. For example, the OWH worked with Medscape Education to create continuing medical education (CME) credits for healthcare professionals, which will better equip them to detect and treat sarcopenia in their patients. Mainstream media has expanded its coverage of sarcopenia to include articles, news stories, and documentaries. According to a February 2022 PubMed article, the US Department of Health and Human Services is one of the top funding agencies in the US, sponsoring 1,604 studies on sarcopenia. From 2022, July 4 will be observed as World Sarcopenia Day. Thus, the elevating awareness regarding sarcopenia is likely to bring new growth trends into the sarcopenia treatment market in the coming years.

The sarcopenia treatment market, by treatment type, is segmented into vitamin D and calcium supplements, protein supplements, vitamin B12 supplements, and others. The vitamin D and calcium supplements segment held the largest share of the market in 2022. The sarcopenia treatment market for this segment is anticipated to record the highest CAGR of 6.5% from 2022 to 2030.
Being a fat-soluble vitamin, vitamin D is crucial for maintaining calcium homeostasis and healthy bone metabolism. The supplementation of vitamin D has been studied as a useful dietary strategy to reduce the risk of sarcopenia. Older adults with suboptimal vitamin D levels are highly susceptible to sarcopenia, often associated with falls, hospitalization, and other adverse effects.

The Public Health Agency of Canada, the US Department of Health and Human Services, and NIH are a few key primary and secondary sources referred to while preparing the report on the sarcopenia treatment market.